Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845042 | 0.96 | THRB (0.58) | THRBTGFBR1MAPK14MAPK13MAPK12 | |
| SCHEMBL29994161 | 0.96 | THRB (0.58) | THRBTGFBR1MAPK14MAPK13MAPK12 | |
| SCHEMBL14844930 | 0.85 | TGFBR1 (0.56) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL2522580 | 0.83 | MAPK14 (0.62) | THRBTGFBR1MAPK14CSNK1DADORA2A | |
| SCHEMBL14844378 | 0.82 | TGFBR1 (0.46) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL24553883 | 0.82 | ADORA2A (0.42) | THRBMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL25223834 | 0.82 | CSNK1D (0.55) | THRBMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL29682984 | 0.82 | MAPK14 (0.46) | THRBMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL24553862 | 0.82 | MAPK14 (0.46) | THRBMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL29683181 | 0.82 | ADORA2A (0.42) | THRBMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-2763993-B1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER IP GMBH (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-9314026-B2 | Heterocyclylpyri(mi)dinylpyrazole | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| EP-2763993-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | Bayer Intellectual Property GmbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| EP-2556073-B1 | BICYCLIC PYRIDINYL PYRAZOLES | BAYER IP GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8507472-B2 | Bicyclic pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-13 | — | — | US | disclosed |
| WO-2013050434-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-11 | — | — | WO | disclosed |
| EP-2556073-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124539-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | THRB 3803/4885TGFBR1 2921/4885MAPK14 851/4885 |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | THRB 2602/4885TGFBR1 3541/4885MAPK14 76/4885 |
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | H1-0, NQO2, CCNI | THRB 4167/4885TGFBR1 1833/4885MAPK14 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.